JP2019501151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501151A5 JP2019501151A5 JP2018529176A JP2018529176A JP2019501151A5 JP 2019501151 A5 JP2019501151 A5 JP 2019501151A5 JP 2018529176 A JP2018529176 A JP 2018529176A JP 2018529176 A JP2018529176 A JP 2018529176A JP 2019501151 A5 JP2019501151 A5 JP 2019501151A5
- Authority
- JP
- Japan
- Prior art keywords
- molar ratio
- antibody
- motomeko
- composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188988A JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500771 | 2015-12-01 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201500787 | 2015-12-07 | ||
| DKPA201500788 | 2015-12-07 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600702 | 2016-11-10 | ||
| DKPA201600701 | 2016-11-10 | ||
| DKPA201600702 | 2016-11-10 | ||
| PCT/EP2016/079517 WO2017093447A1 (en) | 2015-12-01 | 2016-12-01 | Anti-death receptor antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188988A Division JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501151A JP2019501151A (ja) | 2019-01-17 |
| JP2019501151A5 true JP2019501151A5 (enExample) | 2020-01-16 |
Family
ID=58796495
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529087A Active JP7254515B2 (ja) | 2015-12-01 | 2016-12-01 | 抗ｄｒ５抗体およびその使用方法 |
| JP2018529176A Withdrawn JP2019501151A (ja) | 2015-12-01 | 2016-12-01 | 抗デスレセプター抗体およびその使用方法 |
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529087A Active JP7254515B2 (ja) | 2015-12-01 | 2016-12-01 | 抗ｄｒ５抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188988A Active JP7679347B2 (ja) | 2015-12-01 | 2022-11-28 | 抗デスレセプター抗体およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190202926A1 (enExample) |
| EP (4) | EP4467648A3 (enExample) |
| JP (3) | JP7254515B2 (enExample) |
| KR (1) | KR20180098567A (enExample) |
| CN (2) | CN109476737A (enExample) |
| AU (2) | AU2016363770A1 (enExample) |
| BR (2) | BR112018011100A2 (enExample) |
| CA (2) | CA3007033A1 (enExample) |
| IL (1) | IL259713B2 (enExample) |
| MA (1) | MA43365A (enExample) |
| MX (1) | MX2018006333A (enExample) |
| SG (1) | SG11201803956UA (enExample) |
| UA (1) | UA126897C2 (enExample) |
| WO (2) | WO2017093448A1 (enExample) |
| ZA (1) | ZA201803079B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057881A1 (en) * | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| BR112018011100A2 (en) | 2015-12-01 | 2018-12-04 | Genmab B.V. | antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition. |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP7009448B2 (ja) | 2016-08-12 | 2022-02-10 | ヤンセン バイオテツク，インコーポレーテツド | 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法 |
| MX2019014407A (es) * | 2017-06-07 | 2020-02-05 | Genmab Bv | Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados. |
| IL272159B2 (en) | 2017-08-04 | 2026-03-01 | Genmab As | PD-L1 and CD137 binding agents and their use |
| WO2019099374A2 (en) * | 2017-11-14 | 2019-05-23 | University Of Virginia Patent Foundation | Compositions and methods for making and using bispecific antibodies |
| CN109957020A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| MA51666A (fr) | 2018-01-24 | 2020-12-02 | Genmab Bv | Variants polypeptidiques et leurs utilisations |
| AU2019264217B2 (en) | 2018-05-03 | 2026-03-05 | Genmab B.V. | Antibody variant combinations and uses thereof |
| BR112020026432A2 (pt) * | 2018-07-13 | 2021-03-23 | Genmab A/S | variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso |
| JP2022532812A (ja) * | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体組成物 |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| GB201910900D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
| EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
| CN115697419A (zh) * | 2020-05-12 | 2023-02-03 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与癌症疗法组合治疗癌症的用途 |
| CN111778333B (zh) * | 2020-07-03 | 2022-11-18 | 东莞市滨海湾中心医院 | 测定edar表达水平的试剂的应用和试剂盒 |
| EP4185388A1 (en) | 2020-07-23 | 2023-05-31 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| EP4214239A4 (en) * | 2020-10-14 | 2025-07-09 | Univ Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS |
| CN112915211B (zh) * | 2021-02-07 | 2022-05-06 | 成都中医药大学 | 一种pd-l1靶向肽药物偶联物及其合成方法和应用 |
| WO2023023677A1 (en) * | 2021-08-20 | 2023-02-23 | University Of Virginia Patent Foundation | Strategy for highly superior dr5 activation including in tumors and cancers |
| US12410258B2 (en) * | 2023-05-12 | 2025-09-09 | Ganmab A/S | Antibodies capable of binding to OX40, variants thereof and uses thereof |
| GB202315963D0 (en) * | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| WO2025160152A2 (en) * | 2024-01-23 | 2025-07-31 | The Regents Of The University Of California | Fas antibody and its use in treating cancers |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US835A (en) | 1838-07-12 | X i i i x | ||
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US761218A (en) | 1899-10-05 | 1904-05-31 | U S Standard Voting Machine Co | Register or counter. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| IL126383A0 (en) | 1996-04-01 | 1999-05-09 | Genentech Inc | Apo-2li and apo-3 apoptosis polypeptides |
| EP1012274B2 (en) | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| EP1045906B1 (en) | 1998-01-15 | 2008-10-15 | Genentech, Inc. | Apo-2 ligand |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| ZA200002867B (en) | 1999-06-09 | 2001-12-07 | Pfizer Prod Inc | Process for preparing sertraline from chiral tetralone. |
| US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| AU2002256895B2 (en) | 2001-05-18 | 2008-09-18 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| CN100594935C (zh) | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| PT1409544E (pt) | 2001-07-03 | 2009-09-16 | Genentech Inc | Anticorpos de dr4 humanos e suas utilizações |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| US20040019915A1 (en) | 2002-04-01 | 2004-01-29 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| EA012464B1 (ru) * | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| ES2829566T3 (es) | 2005-03-03 | 2021-06-01 | Immunomedics Inc | Anticuerpos L243 humanizados |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| TW200904072A (en) | 2007-07-05 | 2009-01-16 | Ic Plus Corp | System and method for generating interrupt |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| ES2524553T3 (es) | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2010138725A1 (en) | 2009-05-28 | 2010-12-02 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| EP2619226B1 (en) * | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| NZ610153A (en) * | 2010-10-29 | 2014-07-25 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
| DK2838918T3 (da) | 2012-04-20 | 2019-08-12 | Merus Nv | Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| US11180572B2 (en) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| EP2684896A1 (en) * | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| AU2013372331A1 (en) | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| BR112018011100A2 (en) | 2015-12-01 | 2018-12-04 | Genmab B.V. | antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition. |
| JP7277363B2 (ja) | 2016-11-01 | 2023-05-18 | ジェンマブ ビー．ブイ． | ポリペプチド変異体およびその使用 |
| AU2018218345B2 (en) | 2017-02-10 | 2025-04-03 | Genmab B.V. | Polypeptide variants and uses thereof |
-
2016
- 2016-12-01 BR BR112018011100-7A patent/BR112018011100A2/en active Search and Examination
- 2016-12-01 CA CA3007033A patent/CA3007033A1/en active Pending
- 2016-12-01 EP EP24172544.9A patent/EP4467648A3/en active Pending
- 2016-12-01 EP EP16805417.9A patent/EP3383906A1/en not_active Withdrawn
- 2016-12-01 WO PCT/EP2016/079518 patent/WO2017093448A1/en not_active Ceased
- 2016-12-01 IL IL259713A patent/IL259713B2/en unknown
- 2016-12-01 WO PCT/EP2016/079517 patent/WO2017093447A1/en not_active Ceased
- 2016-12-01 UA UAA201807311A patent/UA126897C2/uk unknown
- 2016-12-01 MA MA043365A patent/MA43365A/fr unknown
- 2016-12-01 SG SG11201803956UA patent/SG11201803956UA/en unknown
- 2016-12-01 MX MX2018006333A patent/MX2018006333A/es unknown
- 2016-12-01 JP JP2018529087A patent/JP7254515B2/ja active Active
- 2016-12-01 CN CN201680080715.XA patent/CN109476737A/zh active Pending
- 2016-12-01 KR KR1020187018606A patent/KR20180098567A/ko not_active Ceased
- 2016-12-01 EP EP16805416.1A patent/EP3383905A1/en not_active Withdrawn
- 2016-12-01 EP EP24170877.5A patent/EP4464333A3/en active Pending
- 2016-12-01 BR BR112018011058-2A patent/BR112018011058A2/en active Search and Examination
- 2016-12-01 US US15/780,285 patent/US20190202926A1/en not_active Abandoned
- 2016-12-01 CA CA3007031A patent/CA3007031A1/en active Pending
- 2016-12-01 CN CN201680069617.6A patent/CN108884158A/zh active Pending
- 2016-12-01 AU AU2016363770A patent/AU2016363770A1/en not_active Abandoned
- 2016-12-01 JP JP2018529176A patent/JP2019501151A/ja not_active Withdrawn
- 2016-12-01 US US15/780,268 patent/US20190144554A1/en not_active Abandoned
-
2018
- 2018-05-10 ZA ZA2018/03079A patent/ZA201803079B/en unknown
-
2019
- 2019-06-25 US US16/451,714 patent/US10882913B2/en active Active
-
2020
- 2020-12-01 US US17/108,373 patent/US12247080B2/en active Active
-
2022
- 2022-03-01 US US17/684,238 patent/US20220411522A1/en active Pending
- 2022-11-28 JP JP2022188988A patent/JP7679347B2/ja active Active
-
2024
- 2024-01-15 AU AU2024200261A patent/AU2024200261A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500869A5 (enExample) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| JP2020522543A5 (enExample) | ||
| JP2020502046A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| ES2992868T3 (en) | Combination of tim-4 antagonist and pd-1 antagonist and methods of use | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2018503365A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| RU2017105118A (ru) | Нейтрализация ингибирующих путей в лимфоцитах | |
| JP2018516966A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2016528195A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| RU2016101109A (ru) | Медицинское применение агонистов cd38 | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2021520201A5 (enExample) | ||
| JP2015512412A5 (enExample) | ||
| CN110898226A (zh) | Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法 | |
| JP2021533796A5 (enExample) | ||
| JP2019529416A5 (enExample) |